TMCINMSHealthcare·Medical Devices#83 in industry

Treace Medical Concepts, Inc.

Reports in 11d· 2026-05-08

-24.4% · 90d

$1.92

-0.06 (-3.03%)

After-Hours $1.92(+0.00)

News

(2)

April 2026

Apr 6, 20263 weeks agoARSHealthcare

TREACE MEDICAL CONCEPTS, INC. — ARS Filing

TMCITREACE MEDICAL CONCEPTS, INC.

# 🧾 What This Document Is This is TREACE MEDICAL CONCEPTS' **Annual Report to Shareholders (ARS)**. It's a comprehensive, one-stop document that gives shareholders and potential investors a full picture of the company's performance, strategy, risks, and financial health for the past year. Think of

Read summaryView on SEC EDGAR

Apr 6, 20263 weeks agoDEF 14AHealthcare

TREACE MEDICAL CONCEPTS, INC. — DEF 14A Filing

TMCITREACE MEDICAL CONCEPTS, INC.

# 🧾 What This Document Is This is a **Definitive Proxy Statement (DEF 14A)** for Treace Medical Concepts, Inc. (TMCI). It's an official invitation and information packet for the company's **2026 Annual Meeting of Stockholders**. Think of it as the agenda and briefing materials for a big company vot

Read summaryView on SEC EDGAR

Key Data

Market Cap$124.4M

Open$2.00

Prev Close$1.98

Day Range$1.91 – $2.00

52W Range$1.17 – $7.78

Volume354,204

P/E (TTM)—

EPS$-0.93

Dividend Yield—

Beta0.88

Profit Margin-27.74%

Revenue Growth-9.00%

Price Target$4.25(+121.4%)

Next Earnings2026-05-08(11d)

Analyst Ratings

Hold5 analysts

Buy 1Hold 3Sell 1

About

Treace Medical Concepts, Inc., a medical technology company, designs, manufactures, and markets medical devices in the United States. The company offers Lapiplasty System, enables surgeons to correct all three dimensions of the bunion deformity, stabilize the first TMT joint, and allow return to weight-bearing in a walking boot; minimally invasive products for four bunion classes; Nanoplasty 3D Minimally Invasive Bunion Correction System delivers a reproducible 3D correction of the bunion deformity through a cosmetically appealing; and Percuplasty Percutaneous 3D Bunion Correction System that provides 3D correction of the bunion deformity through percutaneous incisions. It also provides Adductoplasty System, a system designed for the correction of metatarsus adductus deformities and osteoarthritis of the midfoot; SpeedMTP Rapid Compression Implant; SpeedPlate Implant Fixation Platform to address the fusion of larger bones of the midfoot and rearfoot; SpeedPlate Micro-Quad implant, an implant designed for stability and fit in small incision surgical approaches; and SpeedAkin Anatomic Compression Implant. In addition, the company offers The IntelliGuide patient specific instrumentation provides patient-specific, 3D-printed cut guides, and a pre-operative plan for a complete picture of the deformity and correction. Further, it provides FastGrafter Autografter Harvesting System; SpeedRelease Guided Release Instrument; TriTome Triple-Edge Release Instrument; RazorTome 7mm Precision Osteotome; LapiTome Hooked Bone Removal Osteotome; GreatRelease Rapid MTP Release Instrument; CornerChisel Release Tool; NanoRasp MIS Bone Contouring Tool; FeatherRasp Rapid Bone Contouring Instrument; and Akinator Single-cut Akin Wedge Osteotomy tool. Additionally, the company offers biologics and wedges, such as Treace Allograft Wedges; and CortiFuse Flowable Cortical Fibers. Treace Medical Concepts, Inc. was founded in 2013 and is headquartered in Ponte Vedra, Florida.

Healthcare · Medical Devices

450 employees

www.treace.com